ABUSArbutus Biopharma Corporation
Is it safe?
Nothing alarming, nothing pristine: comfortable debt (AA) and typical volatility.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -93% · now 20% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ABUS take a bad year?
Arbutus Biopharma Corporation holds $93M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Interest cover
- 1960×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 45%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $0
- Cash and short-term investments
- $93M
- Net cash
- $93M
- Operating profit, trailing twelve months
- $149M
- Debt / equity
- 0.00×
- Annualised volatilitytwo years of daily moves
- 45%
- Worst drawdown on file
- −93%
- Below its 52-week high
- 20%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.